Longeveron (LGVN) Total Non-Current Liabilities (2022 - 2026)
Longeveron's (LGVN) quarterly Total Non-Current Liabilities came in at $838000.0 in Q1 2026, down 13.25% year-on-year from $966000.0 in Q1 2025, and up 67.94% quarter-over-quarter from $499000.0 in Q4 2025.
Longeveron (LGVN) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Longeveron's Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $838000.0 for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 13.25% year-over-year to $838000.0 in Q1 2026; TTM through Mar 2026 was $838000.0, a 13.25% decrease from a year earlier, with the FY2025 full-year figure at $499000.0, down 54.18% from the prior year.
- Total Non-Current Liabilities grew to $838000.0 in Q1 2026 per LGVN's latest filing, from $499000.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $2.0 million in Q4 2022 and bottomed at $499000.0 in Q4 2025.
- The 5-year median for Total Non-Current Liabilities is $1.2 million (2024), against an average of $1.2 million.
- Across the five-year window, Total Non-Current Liabilities slumped 54.18% in 2025 and fell 13.25% in 2026, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $2.0 million in 2022, then slipped by 29.05% to $1.4 million in 2023, then dropped by 24.79% to $1.1 million in 2024, then slumped by 54.18% to $499000.0 in 2025, then surged by 67.94% to $838000.0 in 2026.
- Per Business Quant, the three latest LGVN Total Non-Current Liabilities figures stand at $838000.0 (Q1 2026), $499000.0 (Q4 2025), and $651000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | 838,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 838,000.00 |
| Dec 31, 2025 | 499,000.00 |
| Sep 30, 2025 | 651,000.00 |
| Jun 30, 2025 | 809,000.00 |
| Mar 31, 2025 | 966,000.00 |
| Dec 31, 2024 | 1.09 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 1.27 Mn |
| Mar 31, 2024 | 1.36 Mn |
| Dec 31, 2023 | 1.45 Mn |
| Sep 30, 2023 | 1.60 Mn |
| Jun 30, 2023 | 1.75 Mn |
| Dec 31, 2022 | 2.04 Mn |